Stockscreener 앱 받기
5.60
0.00%
0.00
시간 외 거래:
5.93
0.33
+5.89%
전일 마감가:
$5.60
열려 있는:
$5.62
하루 거래량:
846.18K
Relative Volume:
1.04
시가총액:
$258.88M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-2.1053
EPS:
-2.66
순현금흐름:
$-78.56M
1주 성능:
+20.17%
1개월 성능:
+0.54%
6개월 성능:
-68.42%
1년 성능:
-67.54%
1일 변동 폭
$5.295
$5.6375
1주일 범위
$4.50
$5.65
52주 변동 폭
$4.4301
$36.25
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
FDMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
5.60 | 258.88M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population - Marketscreener.com
Breakthrough Eye Treatment Data: 4D Molecular's AMD Trial Results Coming February - StockTitan
Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $38.56 - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - Longview News-Journal
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Top US Penny Stocks To Watch In January 2025 - Simply Wall St
Cantor Fitzgerald Estimates FDMT FY2025 Earnings - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
FDMT stock touches 52-week low at $4.48 amid market challenges - MSN
4D Molecular Therapeutics' (FDMT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Weiss Ratings Reaffirms “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Weiss Ratings Reiterates Sell (D-) Rating for 8X8 (NASDAQ:EGHT) - Defense World
Weiss Ratings Reiterates “Sell (D-)” Rating for 89bio (NASDAQ:ETNB) - Defense World
JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
FY2024 Earnings Estimate for FDMT Issued By Leerink Partnrs - Defense World
Equities Analysts Set Expectations for FDMT FY2029 Earnings - Defense World
FY2029 Earnings Estimate for FDMT Issued By HC Wainwright - MarketBeat
Leerink Partnrs Has Bullish Outlook for FDMT FY2024 Earnings - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by Barclays PLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Lowered to “Market Perform” Rating by BMO Capital Markets - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given Buy Rating at HC Wainwright - Defense World
4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Morgan Stanley Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $6.00 - MarketBeat
4D Molecular Therapeutics stock hits 52-week low at $5.2 - Investing.com India
4D Molecular downgraded at BMO on limited population for wet AMD candidate - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Lowered by BMO Capital Markets - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts - Benzinga
Leerink cuts 4D Molecular Therapeutics price target following pipeline updates - Investing.com Australia
Leerink cuts 4D Molecular Therapeutics price target following pipeline updates By Investing.com - Investing.com South Africa
BMO Capital downgrades 4D Molecular Therapeutics stock to Market Perform, cites challenges - Investing.com Canada
BMO Capital downgrades 4D Molecular Therapeutics stock to Market Perform, cites challenges By Investing.com - Investing.com South Africa
4D Molecular Therapeutics refocuses on key drug candidates By Investing.com - Investing.com Australia
4D Molecular, FDA agree on phase 3 design for DME candidate - Seeking Alpha
FDMT4D Molecular Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
4D Molecular Therapeutics refocuses on key drug candidates - Investing.com India
4D Molecular Therapeutics Streamlines Pipeline, Advances Key Eye Disease & CF Programs with $506M Cash - StockTitan
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $42.56 - Defense World
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $42.56 - MarketBeat
Geode Capital Management LLC Sells 24,346 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays PLC Has $1.24 Million Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics stock hits 52-week low at $5.57 By Investing.com - Investing.com Canada
Fmr LLC Sells 1,012,123 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Analyzing Scholar Rock (NASDAQ:SRRK) and 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Critical Review: 4D Molecular Therapeutics (NASDAQ:FDMT) & Candel Therapeutics (NASDAQ:CADL) - Defense World
State Street Corp Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from S&P Biotechnology Select Industry Index - Marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Benzinga
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):